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The NAD+-dependent deacetylase SIRT1 controls
metabolic processes in response to low nutrient
availability. We report the metabolic phenotype of
mice treated with SRT1720, a specific and potent syn-
thetic activator of SIRT1 that is devoid of direct action
on AMPK. SRT1720 administration robustly en-
hances endurance running performance and strongly
protects from diet-induced obesity and insulin resis-
tance by enhancing oxidative metabolism in skeletal
muscle, liver, and brown adipose tissue. These meta-
bolic effects of SRT1720 are mediated by the induc-
tion of a genetic network controlling fatty acid oxida-
tion through a multifaceted mechanism that involves
the direct deacetylation of PGC-1a, FOXO1, and
p53 and the indirect stimulation of AMPK signaling
through a global metabolic adaptation mimicking
low energy levels. Combined with our previous work
on resveratrol, the current study further validates
SIRT1 as a target for the treatment of metabolic disor-
ders and characterizes the mechanisms underlying
the therapeutic potential of SIRT1 activation.
INTRODUCTION
The prevalence of metabolic disorders has been increasing over
the past decades with the adoption of a sedentary lifestyle com-
bined with excessive caloric intake. Increased physical activity
and better feeding habits are clearly a requisite to limit or reverse
weight excess and its deleterious metabolic consequences.
However, dietary management and exercise are not usually suc-
cessful as an intervention, underscoring the need for more
efficient medication to treat metabolic disorders. Intense drug
discovery efforts in the metabolic field currently focus on
enhancing energy expenditure in organs specialized in energy
consumption.
Integrated metabolic networks, which are governed at the
transcriptional level by transcription factors and coregulators,
enable the organism to adapt the metabolic state of differentCell Morgans to nutrient availability (Desvergne et al., 2006; Feige
and Auwerx, 2007; Spiegelman and Heinrich, 2004). Sirtuins,
a family of NAD+-dependent deacetylases, have recently
emerged as integral components of these metabolic networks,
which are particularly important for energy homeostasis (Guar-
ente, 2006; Michan and Sinclair, 2007; Yamamoto et al., 2007).
Sirtuins modulate gene expression according to the energetic
state of the cell, which they sense through NAD+ levels, by de-
acetylating histones as well as transcription factors and coregu-
lators (Feige and Auwerx, 2008). The founding member of the
family, SIRT1, promotes longevity in response to caloric restric-
tion in species ranging from yeast to mammals, and it is be-
lieved that these protective actions may result, at least in
part, from the regulation of energy homeostasis (Guarente,
2006). Consistently, SIRT1 is an important regulator of meta-
bolic processes such as lipolysis, fatty acid oxidation (FAO),
mitochondrial activity, and gluconeogenesis (Baur et al., 2006;
Gerhart-Hines et al., 2007; Lagouge et al., 2006; Picard et al.,
2004; Rodgers et al., 2005; Rodgers and Puigserver, 2007),
which occur in response to an intracellular rise in the NAD+/
NADH ratio when energy supply is low. As SIRT1 is activated
by caloric restriction, the ability to allosterically induce its activ-
ity opens the possibility to pharmacologically mimic low ener-
getic levels and, thereby, stimulate fat utilization to prevent
diet-induced obesity and its associated disorders. This concept
has been validated in mice treated with the natural polyphenol
resveratrol, which activates SIRT1 and protects from obesity by
inducing oxidative mitochondrial metabolism through deacety-
lation of the PPARg coactivator 1a (PGC-1a) (Baur et al.,
2006; Lagouge et al., 2006). The observation that resveratrol
can activate both SIRT1 and the AMP-activated protein kinase
(AMPK) leaves open the question of what degree of efficacy is
due to the direct activation of SIRT1 (Baur et al., 2006). To
address this issue, we have used a selective synthetic SIRT1
activator with improved on-target selectivity, potency, and effi-
cacy, and we have tested its metabolic actions for protection
against diet-induced obesity and metabolic disorders in mouse
models. Our results demonstrate that SRT1720 administration
protects from diet-induced obesity and its negative conse-
quences on glucose homeostasis by primarily promoting fat
consumption in skeletal muscle, liver, and brown adipose tissue
(BAT).etabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc. 347
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SRT1720 Protects from Metabolic DisordersFigure 1. SRT1720 Is a High-Affinity Specific Activator of SIRT1
(A) Structure of the SRT1720 compound.
(B) The action of resveratrol (RSV) and SRT1720 on SIRT1 activity was assessed in a mass spectrometry-based deacetylation assay of a 20 residue peptide.
(C–E) Oxygen consumption was measured in C2C12 myotubes treated for 24 hr with 10 nM SRT1720 before or after a 1 hr treatment with the uncoupler FCCP at
500 nM (C), in combination with 5 mM resveratrol (RSV) or 2 mM metformin (Metf) (D), or 48 hr following an adenoviral infection with control or SIRT1 shRNAs (E).
(F) The activation of the AMP-activated protein kinase (AMPK) was assessed in C2C12 myotubes treated with vehicle, vehicle and 500 mM AICAR (15 min), 5 mM
resveratrol, or 50 nM SRT1720 by evaluating the phosphorylation state of AMPKa and its target acetylCoA carboxylase (ACC) by western blotting.
(G) The acute action of SRT1720 on AMPK activation was evaluated after a single administration at 500 mg/kg in wild-type male C57BL/6J 4 hr prior to sacrifice.
AICAR was administered as a positive control 4 hr prior to sacrifice at 500 mg/kg. AMPKa and ACC phosphorylation was analyzed by western blot in gastroc-
nemius muscle.
Error bars represent SEM, and significant differences to untreated controls (p < 0.05) are indicated by an asterisk. Other significant differences are indicated by
a pound symbol.RESULTS
SRT1720 Is a Potent and Specific Activator of SIRT1
Given the beneficial metabolic actions of the naturally occurring
SIRT1 activator resveratrol, we selected a more potent and effi-
cacious SIRT1 activator identified in a small molecule screen for
SIRT1 agonists (Milne et al., 2007; Figure 1A). In a mass spec-
trometry deacetylation assay, SRT1720 induced the activity of
SIRT1 by 8.7-fold, whereas the activation by resveratrol was lim-
ited to a 2.6-fold increase (Figure 1B). Importantly, this increased
efficacy was also associated with enhanced potency, as the
EC1.5 for SIRT1, which represents the concentration required
to reach a 50% increase over basal, was 0.23 mM for SRT1720
but 47.6 mM for resveratrol.
Since resveratrol protects against metabolic disorders by in-
ducing energy expenditure, the action of SRT1720 was validated348 Cell Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevierin a cellular model utilizing oxygen consumption as a readout of
energy expenditure. In C2C12 myotubes, SRT1720 significantly
stimulated oxygen consumption both in basal conditions and af-
ter stimulation with the chemical uncoupler FCCP (Figure 1C). In-
terestingly, this effect was observed after 24 hr of treatment, but
not after a short 1 hr treatment (data not shown), a timing suggest-
ing that the actions of SRT1720 on oxygen consumption are me-
diated by transcriptional mechanisms. In addition, the SRT1720-
mediated stimulation of oxygen consumption was totally blocked
by the ATP synthase inhibitor oligomycin (Figure S1A available
online). To evaluate the specificity of SRT1720, we first analyzed
whether it could synergize with other stimulators of cellular respi-
ration in C2C12 cells (Figure 1D). The actions of SRT1720 were
additive to those of the AMPK activator metformin, but not to
those of resveratrol, suggesting that SRT1720 induces oxygen
consumption via SIRT1. The direct involvement of SIRT1 in theInc.
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SRT1720 Protects from Metabolic DisordersFigure 2. SRT1720 Prevents Diet-Induced Obesity in Male C57BL/6J Mice
(A) Body weight evolution of animals fed with a HF diet alone or supplemented with SRT1720 at 100 or 500 mg per kg of body weight per day (mkd) (n = 10).
(B) Fat mass was measured by dexascan before and after 13 weeks of treatment (n = 10).
(C) Average daily food intake (n = 10).
(D) Spontaneous activity of mice represented by the average horizontal and vertical activities monitored over a 24 hr period after 13 weeks of treatment (n = 8).
(E) Energy expenditure was evaluated by the measurement of oxygen consumption (VO2), of carbon dioxide release (VCO2), and by the calculation of the respi-
ratory quotient (RQ) over a 12 hr period after 10 weeks of treatment. The adjacent bar graphs represent the average for each group (n = 8).
Error bars represent SEM, and significant differences compared to untreated controls (p < 0.05) are indicated by an asterisk.response to SRT1720 was formally demonstrated using a shRNA
knockdown of SIRT1, which ablated the SRT1720-mediated in-
crease of oxygen consumption (Figure 1E). In addition, we evalu-
ated the action of SRT1720 on AMPK, which has been demon-
strated to be activated by resveratrol independently of SIRT1
(Baur et al., 2006; Dasgupta and Milbrandt, 2007). Unlike resver-
atrol and the synthetic AMPK activator AICAR, SRT1720 did not
induce a significant level of phosphorylation of the a subunit of
AMPK and of its downstream target acetylCoA carboxylase
(ACC) in C2C12 myotubes at various time points and concentra-
tions (Figures 1F and S1B). Furthermore, and perhaps most im-
portantly, acute SRT1720 administration in vivo did not enhance
AMPK signaling either (Figure 1G). Altogether, these resultsCelldemonstrate that SRT1720 is a potent and specific SIRT1 activa-
tor that does not directly stimulate AMPK.
SRT1720 Protects from Diet-Induced Diabesity
The metabolic actions of SRT1720 were then evaluated by ad-
ministering the compound by food admixture to wild-type
C57BL/6J male mice challenged with a high-fat (HF) diet. The in-
corporation of the compound to the diet was adjusted weekly to
food intake and body weight in order to achieve average expo-
sures of 100 and 500 mg/kg/day (mkd). While the low dose
only partially protected from weight gain after 10 weeks of
treatment, the high dose totally prevented diet-induced obesity
by inhibiting fat accumulation (Figures 2A and 2B). Importantly,Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc. 349
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SRT1720 Protects from Metabolic Disordersthis effect on body weight did not result from altered feeding be-
havior or increased locomotor activity (Figures 2C, 2D, and S2A).
Enzymes associated with hepatic injury or tissue breakdown
were normal during the study, indicating that SRT1720 was
well tolerated and that the efficacy observed was not through
a toxic response (Figure S2B). In addition, despite slightly ele-
vated fecal lipid content, the histology of the gut was not altered
by the treatment (Figures S2C and S2D), suggesting that
SRT1720 did not significantly alter intestinal nutrient uptake.
The lean phenotype of SRT1720-treated mice fed HF diet cor-
related with enhanced energy expenditure, as both oxygen con-
sumption and carbon dioxide release were increased by the
treatment (Figure 2E). This stimulation of the metabolic rate oc-
curred without changes in the respiratory quotient (RQ), which
reflects the relative use of carbohydrates versus lipids as
a source of energy. Since mice on HF diet use fatty acids as
the main source of energy, the RQ of untreated animals was
close to 0.7, the theoretical lower limit of this parameter corre-
sponding to lipid utilization solely. To evaluate the action of
SRT1720 on fuel preference in a setting where RQ variations
were not masked by HF content in the diet, we treated mice on
regular chow diet and repeated indirect calorimetry either in
fed animals or in animals where endogenous fat utilization was
stimulated by short-term fasting (Figure S3B). The RQ was higher
on chow than on HF diet (0.95 versus 0.75, respectively) and was
only slightly lowered by SRT1720 in fed conditions. However, the
RQ of chow-fed mice decreased robustly upon fasting, demon-
strating that SRT1720 can shift the fuel preference toward fatty
acids.
Since diet-induced obesity exerts detrimental actions on
plasma lipid profiles and glucose homeostasis, we analyzed
whether SRT1720 could normalize these parameters. Lipid pro-
files in the plasma of SRT1720-treated mice were improved as
both triglyceride and cholesterol levels were reduced on HF
diet (Figure 3A). Reduced cholesterol concentrations resulted
mainly from a decrease in LDL cholesterol (Figure 3A). On
chow diet, cholesterol levels were unaffected by SRT1720
(data not shown), but triglyceride and VLDL levels were lowered
by SRT1720 in chow-fed mice (Figure S3C). SRT1720 also pre-
vented the negative impact of HF feeding on glucose homeosta-
sis as fasting blood glucose and insulin were both reduced
(Figure 3B). In addition, mice treated with SRT1720 had a better
tolerance to a glucose load, which was particularly prominent in
the late time points of an intraperitoneal glucose tolerance test
(IP-GTT) (Figure 3C). Together with the reduced fasting insulin
levels, this observation suggested that SRT1720 improves glu-
cose homeostasis by enhancing insulin sensitivity. This hypoth-
esis was confirmed in a hyperinsulinemic-euglycemic clamp in
which the glucose infusion rate, which reflects the sensitivity of
peripheral tissues to insulin, was significantly enhanced by
SRT1720 treatment (Figure 3D). Since obesity and insulin resis-
tance are intricately linked, we demonstrated that improved glu-
cose tolerance at 500 mkd was not an indirect consequence of
reduced adiposity since glucose tolerance was also improved
in an IP-GTT in chow-fed mice treated with SRT1720 for 3 weeks,
in which body weight was not substantially affected (Figure S3E).
In addition, the direct action of SRT1720 on insulin sensitivity
was confirmed by the increased glucose infusion rate in a hyper-
insulinemic-euglycemic clamp in mice treated for 3 weeks on HF350 Cell Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Indiet, for which the average body weight difference between
groups does not exceed 3 g (Figure 3E). In this experiment, triti-
ated glucose was used as a tracer to evaluate whole-body
glucose turnover before and after insulin perfusion (Figure 3F).
Although the glucose turnover only tended to increase in
SRT1720-treated mice, the ability of insulin to suppress endog-
enous glucose production was significantly enhanced upon
SRT1720 administration, demonstrating that SRT1720 improves
hepatic insulin sensitivity. Furthermore, insulin sensitivity was
also enhanced in the skeletal muscle, as insulin-stimulated glu-
cose uptake, measured through 14C-2-deoxy-glucose uptake,
was higher in the gastrocnemius muscle of SRT1720-treated
mice (Figure 3G).
Altogether, these results demonstrate that activating SIRT1 by
SRT1720 in a context of caloric excess strongly protects from fat
accretion. Furthermore, our data show that SRT1720 improves
glucose tolerance and insulin sensitivity both in the context of
HF and chow feeding.
SRT1720 Promotes Energy Expenditure
in Metabolic Tissues
A key factor controlling energy homeostasis is the balance be-
tween caloric intake and expenditure, which modulates fat accu-
mulation and peripheral insulin sensitivity. Therefore, we ana-
lyzed the actions of SRT1720 on lipid accumulation and energy
expenditure in organs that integrate the metabolic response of
the entire body. The mass of epididymal white adipose tissue
(WAT) from mice, where HF feeding was thwarted by 500 mkd
SRT1720, was three times lower than that of control mice on
HF diet only (Figure S4A). In addition, this reduced fat accumula-
tion was associated with smaller adipocyte size (Figure S4B),
a feature that correlates with leanness and insulin sensitivity.
Since smaller adipose tissue could be linked to altered adipo-
genesis or enhanced lipolysis, we verified the expression of
well-established markers of these processes in WAT. SRT1720
did not induce major impairments in the ability of adipocytes to
differentiate and store lipids, as despite a slight induction of per-
oxisome proliferator-activated receptor (PPAR) g expression,
the levels of its downstream targets C/EBPa, aP2, and CD36
were not affected (Figure S4C). Consistent with the previous
demonstration of a positive action of SIRT1 on lipolysis (Picard
et al., 2004), the RNA levels of the hormone-sensitive lipase
were enhanced in SRT1720-treated mice. The enhanced ex-
pression of oxidative markers, such as the PGC-1 coactivators
and the nuclear receptor PPARb/d, suggests that SRT1720
could promote energy expenditure in WAT. Nevertheless, the
minor contribution of WAT to whole-body energy consumption
suggests that this regulation is not the primary cause of the
lean phenotype, which most likely results from the reduced
availability of lipids for storage.
Since the absence of fat accumulation in SRT1720-treated
mice suggested that energy expenditure could be stimulated,
we analyzed the metabolic capacities of energy dissipating or-
gans. Skeletal muscle function was examined utilizing endur-
ance and locomotor tests (Figure 4A). Mice treated with
SRT1720 on HF diet ran approximately twice the distance as
control animals in an endurance exercise test. To rule out an in-
direct effect of weight difference on running capacities, we exer-
cised chow-fed mice treated for 6 weeks with SRT1720 andc.
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SRT1720 Protects from Metabolic DisordersFigure 3. SRT1720 Improves Glucose and Cholesterol Homeostasis
(A and B) Lipid (A) and glucose and insulin (B) levels were measured after 16 hr of fasting in the plasma of mice treated with HF diet alone or supplemented with
SRT1720 at 100 or 500 mkd for 6 weeks (n = 8).
(C) Intraperitoneal glucose tolerance test on mice treated with SRT1720 as in (A) for 12 weeks and injected with 2 g glucose/kg after 12 hr of fasting. The adjacent
bar graph represents the average area under the curve (n = 10).
(D) Insulin sensitivity evaluated through the average glucose infusion rate at equilibrium in a hyperinsulinemic-euglycemic clamp (18 mU insulin/min/kg) in mice
treated with SRT1720 as in (A) for 20 weeks. The equilibrium at clamp is reflected by the euglycemia shown in the adjacent graph (n = 5).
(E–G) A hyperinsulinemic-euglycemic clamp (18 mU insulin/min/kg) was performed using radioactive tracers in mice treated with SRT1720 as in (A) for 3 weeks.
The evaluation of whole-body glucose turnover (F) and glucose uptake in tissues (G) was performed using 3H-glucose and 14C-2-deoxy-glucose tracers, respec-
tively.
Error bars represent SEM, and significant differences compared to untreated controls (p value < 0.05) are indicated by an asterisk.demonstrated that the animals on SRT1720 also became much
better endurance runners (Figure S3D). Increased muscle
strength in the grip strength test, as well as better locomotor be-
havior, as concluded from the increased latency to fall in a ro-
tarod test and the reduced time to hind paw equilibration in
a string test, all provide additional support to the improved mus-
cle function upon SRT1720 administration. Since improved en-
durance can result from variations in the proportion of glycolytic
and oxidative muscle fibers, we evaluated whether SRT1720 can
promote fiber type switching through a succinate dehydroge-
nase (SDH) staining of muscle fibers (Figure 4B). The proportion
of blue-stained oxidative fibers was higher in the gastrocnemius
of SRT1720-treated mice, whereas it could not be further en-
hanced by the treatment in the purely oxidative soleus muscle.
The shift toward more oxidative fibers occurred without changes
in mitochondrial density (Figures S5B and S5C). In addition,Cellcitrate synthase (Figure S5D) and cytochrome C oxidase
(Figure S5E) activities were not altered in SRT1720-treated
mice, suggesting that SRT1720 enhances oxidative metabolism
through other mitochondrial mechanisms.
Therefore, to understand the molecular basis of the improved
endurance and fiber type switch, we analyzed gene expression
from gastrocnemius skeletal muscle (Figure 4D). Despite an in-
creased mRNA level of cytochrome C oxidase (Cox IV), the ex-
pression of most of the genes controlling mitochondrial function
and oxidative phosphorylation (OxPhos) was only minimally af-
fected by SRT1720 treatment. We observed, however, a switch
in the contractile phenotype of the muscle fibers, as SRT1720-
treated mice expressed higher mRNA levels of both troponin I
slow (TropoIslow) and type I and IIa myosin heavy chains
(MyHC), three markers of slow-twitch oxidative fibers, but had
reduced expression of the mRNA encoding the fast-twitchMetabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc. 351
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SRT1720 Protects from Metabolic DisordersFigure 4. SRT1720 Improves Endurance and Locomotor Functions
(A) Endurance, evaluated by the average distance run until exhaustion on a treadmill, and locomotor functions, evaluated through the string, the grip strength, and
the rotarod tests, were performed in mice treated for 15 weeks with HF diet alone or supplemented with either 100 or 500 mkd SRT1720 (n = 10).
(B) Representative succinate dehydrogenase staining on gastrocnemius (gastro) and soleus (sol) muscle sections.
(C) Fatty acid oxidation rates were measured in C2C12 cells treated for 24 hr with vehicle (white bars) or 10 nM SRT1720 (black bars) using oxygen consumption
as a readout (n = 10).
(D) Gene expression in gastrocnemius skeletal muscle expressed relative to b2-microglobulin in the same mice as in (C). Abbreviations not used previously: HK,
hexokinase; IDH, isocitrate dehydrogenase; Cyt C, cytochrome C; ATP5g1, ATP synthase subunit 5g1; CPT-1, carnitine palmitoyl transferase 1.
Error bars represent SEM, and significant differences compared to untreated controls (p < 0.05) are indicated by an asterisk.glycolytic marker MyHC type IIb. Interestingly, this switch corre-
lated with a lower expression of the glycolytic enzyme 6-phos-
phofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and
an increased expression of the pyruvate dehydrogenase kinase
4 (PDK4) mRNA, which favors the utilization of fatty acids over
glucose by lowering the utilization of pyruvate through inhibition
of the pyruvate dehydrogenase complex. Moreover, SRT1720
also stimulated the expression of genes promoting FAO, such
as PPARa and the medium- and long-chain acyl-CoA dehydro-
genases (MCAD and LCAD), to concomitantly increase the flux
of fatty acid utilization in the muscle. In line with these observa-
tions, the genes upregulated by SRT1720 at the genome-wide
level were enriched in genes from the mitochondrial b-oxidation
pathway (Figure S5A). Moreover, these gene expression changes
correlated functionally with enhanced FAO as SRT1720 in-
creased palmitate oxidation rates in muscle cells (Figure 4C).
Therefore, SRT1720 induces a switch toward more oxidative352 Cell Metabolism 8, 347–358, November 5, 2008 ª2008 Elseviermuscle fiber types by primarily stimulating FAO rather than by
improving mitochondrial function per se.
Given the important contribution of hepatic FAO to whole-body
energy expenditure, we evaluated whether the beneficial effects
of SRT1720 on muscle oxidative functions could also be ob-
served in the liver. Reduced staining with oil red O confirmed
that hepatic fat storage in lipid droplets was significantly reduced
in SRT1720-treated mice (Figure 5A), predominantly because the
accumulation of triglycerides was inhibited (Figure 5B). In con-
trast, hepatic free fatty acid levels were not altered. We then
tested the different metabolic pathways that SRT1720 could reg-
ulate to promote energy expenditure. The expression of genes
controlling glycolysis was not altered in SRT1720-treated mice
(Figure 5C), and gluconeogenesis was not consistently changed,
as the expression of the phosphoenolpyruvate carboxykinase
(PEPCK) was modestly enhanced, while that of glucose-6-phos-
phatase (G6Pase) remained unchanged. SRT1720, however, hadInc.
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SRT1720 Protects from Metabolic DisordersFigure 5. SRT1720 Promotes Hepatic Oxidative Functions
(A) Representative oil-red-O staining of liver sections from mice fed for 20 weeks with HF diet alone or supplemented with SRT1720 at 100 or 500 mkd.
(B) Hepatic lipid content was measured following Folch’s extraction (n = 10).
(C) Gene expression in liver expressed relative to b-actin and 36B4 (n = 10). Abbreviations not used previously: GCK, glucocarboxykinase; LPK, L-type pyruvate
kinase; Ndufb5, NADH dehydrogenase 1b5; AdipoR, adiponectin receptors.
Error bars represent SEM, and significant differences compared to untreated controls (p < 0.05) are indicated by an asterisk.a strong impact on the expression of enzymes and regulators
controlling FAO (Figures 5C and S5A). The expression of the
two nuclear receptors PPARa and b/d was robustly induced in
the liver of SRT1720-treated mice. The functional relevance of
this induction was validated by an increased expression of direct
PPAR target genes. Among these, SRT1720 exerted particularly
prominent actions on the mRNA expression of PDK4 and the
fibroblast growth factor 21 (FGF21), an antiobesity signaling mol-
ecule secreted by the liver in response to PPARaactivation (Khar-
itonenkov and Shanafelt, 2008). Consistent with what was ob-
served in the muscle, the actions of SRT1720 on hepatic
oxidative metabolism occurred with rather discrete changes in
mitochondrial function and OxPhos (Figure 5C), suggesting that
this SIRT1 activator stimulates hepatic energy expenditure by pri-
marily acting on the degradation of fatty acids.
BAT is another major tissue where energy, coming predomi-
nantly from fat, is dissipated to maintain body temperature. Con-
sistent with the lean phenotype induced by the treatment, mice
on SRT1720 had smaller brown adipocytes, in which the size
of lipid droplets was reduced (Figures 6A and 6B). Similar to
what was observed in skeletal muscle, the number of mitochon-
dria did not seem to be affected by SRT1720 despite a lower
density caused by reduced lipid droplet size (Figure 6B). Low
fat accumulation in BAT correlated with the global activation of
a network of genes controlling energy expenditure (Figure 6C).
The expression of several transcription factors, including PPARa
and g, thyroid hormone receptors (TR) a and b, and PGC-1a and
b, was strongly activated in the BAT of SRT1720-treated ani-
mals. In addition, the upregulation of type 2 deiodinase (DIO2),
an enzyme that converts inactive thyroid hormone T4 into T3,
most likely synergizes with the elevated TR levels to promote
thyroid hormone signaling. Several direct targets of PGC-1,
such as the estrogen-related receptor a (ERRa), the mitochon-Celldrial transcription factor A (mTFA), and the superoxide dismu-
tases (SOD) 1 and 2, were also significantly induced. Surpris-
ingly, the expression of the uncoupling protein (UCP) 1, which
uncouples mitochondrial electron transport from ATP synthesis
to dissipate energy as heat, or that of its homolog UCP2 were
not altered. In contrast, the expression of UCP3 was robustly in-
creased by SRT1720, contributing potentially to energy dissipa-
tion by short-circuiting OxPhos. SRT1720 also potently stimu-
lated the expression of genes controlling FAO, whereas its
action on components of the mitochondrial electron transport
chain was fairly limited. In SRT1720-treated mice, the excess
of calories from the diet is most likely transformed to NADH
and FADH2 by enhanced fat oxidation and generates a proton
gradient in mitochondria, which can subsequently be eliminated
through UCP3-mediated uncoupling. In line with these observa-
tions, SRT1720 stimulated oxygen consumption in primary
brown adipocytes (Figure 6D). SRT1720 treatment did not
change the body temperature at night. The physiological circa-
dian temperature drop during daytime, because of inactivity
and spontaneous fasting as normally observed in control mice,
was, however, amplified by the treatment, which lowered body
temperature by 1C (Figures 6E and 6F). Since this tempera-
ture phenotype could not be recapitulated in a short-term exper-
iment where SRT1720 was administered by daily gavage, it is
likely that the temperature phenotype from Figure 6F results
from low fat accumulation in SRT1720-treated mice, which
does not allow sufficient insulation and lipolysis to generate
heat during resting periods.
SRT1720 Administration Mechanistically Mimics
Low Energy Levels
SIRT1 has emerged as a pleiotropic modulator of transcription
factor and coregulator activity, which it regulates throughMetabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc. 353
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SRT1720 Protects from Metabolic DisordersFigure 6. SRT1720 Stimulates Energy Expenditure from the Brown Adipose Tissue
(A and B) Representative hematoxylin and eosin staining (A) and electronic micrographs (B) from BAT sections of mice fed for 20 weeks with HF diet alone or
supplemented with SRT1720 at 100 or 500 mkd (n = 10). Abbreviations not used previously: L, lipid droplet; M, mitochondrium; N, nucleus; C, capillary.
(C) Gene expression in BAT expressed relative b2-microglobulin (n = 10). Abbreviation not used previously: NRF1, nuclear respiratory factor 1.
(D) Oxygen consumption was measured in primary brown adipocytes treated for 24 hr with vehicle (white bars) or 10 nM SRT1720 (black bars) before or after a 1 hr
treatment with the uncoupler FCCP at 500 nM.
(E) Rectal temperature measured at 11 a.m. (n = 10).
(F) Body temperature monitored by telemetry over 72 hr. The adjacent bar graph represents the average area under the curve over the diurnal and nocturnal
phases, respectively (n = 5).
Error bars represent SEM, and significant differences compared to untreated controls (p < 0.05) are indicated by an asterisk.354 Cell Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc.
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SRT1720 Protects from Metabolic DisordersFigure 7. SRT1720 Promotes the Deacetylation of SIRT1 Targets and Indirectly Activates AMPK
(A–C) Acetylation levels of SIRT1 targets in response to chronic SRT1720 administration over 20 weeks. The acetylation of PGC-1a (A) and FOXO1 (B) was an-
alyzed by immunoprecipitation from nuclear extracts from the gastrocnemius muscle of control mice or mice treated with SRT1720 at 500 mg per kg of body
weight per day (mkd), followed by an immunoblot against acetylated lysine residues (top panel) or PGC-1a/FOXO1 (lower panel). P53 acetylation levels (C) were
determined by direct immunoblotting against acetylated (top panel) or total (lower panel) p53 from hepatic nuclear extracts of the same animals as in (A) and (B).
(D–F) AMPK activation in mice treated for over 20 weeks with SRT1720 was evaluated in the gastrocnemius muscle (D), the liver (E), and BAT (F) by analyzing
AMPKa and ACC phosphorylation levels by western blot.
(G) ATP and ADP concentrations were measured using a luciferase-based assay from acid-extracted BAT samples from mice described in (D)–(F) (n = 8).
Error bars represent SEM, and significant differences compared to untreated controls (p < 0.05) are indicated by an asterisk.deacetylation (Feige and Auwerx, 2008). Since our gene profiling
experiments suggested that the metabolic effects of SRT1720
rely at least in part on transcriptional mechanisms, we analyzed
the acetylation levels of metabolically relevant transcriptional
targets of SIRT1 in response to SRT1720. One of the best char-
acterized metabolic targets of SIRT1 is PGC-1a, which is acti-
vated by SIRT1-mediated deacetylation (Gerhart-Hines et al.,
2007; Lagouge et al., 2006; Rodgers et al., 2005, 2008). Endog-
enous PGC-1a immunoprecipitated from the gastrocnemius
muscle of mice treated with SRT1720 was robustly deacetylated
(Figure 7A). In addition, SRT1720 also promoted the deacetyla-
tion of the Forkhead transcription factor family O1 (FOXO1) in
skeletal muscle and of p53 in liver (Figures 7B and 7C), two other
SIRT1 targets implicated in the coordination of metabolic ho-
meostasis (Bensaad and Vousden, 2007; Feige and Auwerx,
2008; Frescas et al., 2005; Gross et al., 2008; Luo et al., 2001;
Qiao and Shao, 2006; Vaziri et al., 2001). The ability of
SRT1720 to induce the deacetylation of three established
SIRT1 targets in different tissues, therefore, unequivocally dem-
onstrates that it is a potent activator of SIRT1 in vivo.
SIRT1 is a well-recognized effector of the beneficial effects of
calorie restriction on homeostasis (Guarente, 2006), and it has
been speculated that treatment with SIRT1 activators might trig-
ger metabolic pathways activated by low energetic levels (Chen
and Guarente, 2007). Given that the systemic response to caloric
deprivation is a metabolic switch toward the oxidation of lipids
released from adipose tissue stores, SRT1720 seems to induce,
at least in part, metabolic pathways activated by low energetic
levels. Since AMPK is another key activator of fatty acid catabo-Celllism that senses low energetic levels, we tested whether pro-
longed SRT1720 administration could modulate AMPK activity.
Although AMPK was not activated by SRT1720 treatment in cel-
lular models or upon acute exposure in vivo (Figures 1F and 1G),
the phosphorylation of AMPKa and its downstream target ACC
was increased in the muscle, liver, and BAT of mice treated
chronically with 500 mkd SRT1720 (Figures 7D, 7E, and 7F).
Given that ATP and ADP levels were reduced in BAT of
SRT1720-treated mice (Figure 7G), it is likely that SRT1720 tar-
gets AMPK indirectly through the metabolic status.
Altogether, these observations, therefore, support the con-
cept that the SIRT1 activator SRT1720 acts as a calorie restric-
tion mimetic that favors fat utilization by promoting the direct
deacetylation of multiple SIRT1 targets and by inducing chronic
metabolic adaptations that involve the indirect activation of
AMPK.
DISCUSSION
Pharmacologically targeting transcriptional networks to regulate
global gene expression programs favoring energy expenditure
represents an attractive concept to combat metabolic diseases.
In this context, SIRT1 has emerged as an interesting target with
the demonstration that the naturally occurring SIRT1 activator
resveratrol protects from diet-induced metabolic disorders
(Baur et al., 2006; Lagouge et al., 2006). At present, it is, how-
ever, difficult to distinguish how many of the effects of resveratrol
are specifically mediated by SIRT1 versus other resveratrol tar-
gets such as AMPK (Baur et al., 2006; Dasgupta and Milbrandt,Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevier Inc. 355
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SRT1720 Protects from Metabolic Disorders2007). A new generation of selective synthetic SIRT1 activators
structurally unrelated to resveratrol and with improved potency,
efficacy, and specificity have recently been developed (Milne
et al., 2007). In the present study, we have analyzed the global
metabolic actions of SRT1720, a member of this new generation
of agonists that is more potent and efficacious than resveratrol
and exhibits higher specificity with respect to off-target activa-
tion of other sirtuin homologs or AMPK (Milne et al., 2007; Fig-
ure 1). When incorporated in the diet at a dose of 100 mkd,
SRT1720 improves glucose homeostasis by enhancing insulin
sensitivity in mice where insulin resistance was induced by HF
feeding, as also reported in other rodent models of type 2 diabe-
tes using daily oral administration (Milne et al., 2007). These an-
tidiabetic actions are even more pronounced at a dose of
500 mkd, which also protects from the weight gain induced by
HF feeding. Importantly, the antidiabetic actions of SRT1720
are not the indirect consequences of reduced fat accretion, as
they can be recapitulated after short-term treatment or under
chow diet, where weight differences between groups are mini-
mal. By selectively activating SIRT1, SRT1720 treatment, there-
fore, mimics the phenotype that is induced by resveratrol admin-
istration, as oxidative metabolism and energy expenditure are
enhanced in mice treated with both compounds, leading to pro-
tection from diet-induced obesity and to improved muscle per-
formance. Although it can be surprising to observe that high
doses of SRT1720 are required to induce physiological effects
in vivo despite a high affinity for SIRT1, this apparent discrep-
ancy relates to the pharmacokinetics of the compound. The
plasma concentrations of SRT1720 only reach nanomolar con-
centrations at both doses administered, presumably because
of rapid metabolism and/or distribution, and further chemical re-
finement of the structure of SRT1720 will be required to enhance
bioavailability. In addition, the observation that SRT1720 tran-
siently affects core body temperature and spontaneous locomo-
tor activity could constitute potential side effects for the treat-
ment of metabolic disorders but could also be explored for
other therapeutic interventions.
Despite a high correlation of the phenotypic outputs induced
by resveratrol and SRT1720, which involve in both cases en-
hanced energy expenditure in muscle, liver, and BAT, the phys-
iological mechanisms through which these compounds exert
their actions only partially overlap. The most prominent differ-
ence relates to the way through which both compounds induce
oxidative metabolism. Resveratrol acts primarily on mitochon-
drial biogenesis and function by activating PGC-1a and, subse-
quently, inducing the expression of regulators of mitochondrial
metabolism such as NRF1, ERRa, and mTFA (Lagouge et al.,
2006). In contrast, SRT1720 seems to have a more limited
activity on mitochondrial density. It is, therefore, plausible that
off-target effects, such as the direct activation of AMPK, are re-
quired for the actions of resveratrol on mitochondrial biogenesis.
It seems that the activation of SIRT1 by SRT1720 acts upstream
on oxidative metabolism by activating the pathways controlling
the oxidation of fatty acids. Consistently, SRT1720 promotes
palmitate oxidation in cellular models, and the nuclear receptors
PPARa and PPARb/d, two major regulators of FAO (Evans et al.,
2004; Feige et al., 2006), are upregulated by SRT1720 in several
tissues with high rates of fatty acid utilization. Moreover, many
oxidative PPAR target genes are also induced, suggesting that356 Cell Metabolism 8, 347–358, November 5, 2008 ª2008 Elsevier ISIRT1 activation by SRT1720 drives a global oxidative program
by stimulating fatty acid utilization. In this context, the strong en-
hancement of endurance and running capacities observed in
SRT1720-treated mice most likely results both from a switch in
the contractile phenotype of muscle fibers and from fast-twitch
glycolytic fibers acquiring more resistance to fatigue by switch-
ing their substrate preference toward fatty acids. At the molecu-
lar level, the deacetylation of PGC-1a and FOXO1 by SRT1720
most probably plays a prominent role in this oxidative switch of
skeletal muscle fibers, as the metabolic actions of these tran-
scriptional regulators are stimulated by SIRT1-mediated deace-
tylation, leading to the promotion of oxidative muscle function
(Frescas et al., 2005; Gross et al., 2008; Handschin et al.,
2007; Lin et al., 2002; Rodgers et al., 2008). The SRT1720-medi-
ated induction of PPARa expression could be linked to the
coactivation of the PPARa promoter by PGC-1a (Huss et al.,
2004). In addition, activation of PGC-1a signaling most likely syn-
ergizes with increased PPAR expression, as PGC-1a is a coacti-
vator of PPARa- and PPARb/d-mediated FAO (Vega et al., 2000;
Wang et al., 2003). Despite the induction of PGC-1a expression
in various metabolic tissues of SRT1720-treated mice and the
ability of SRT1720 to promote PGC-1a deacetylation, it is inter-
esting to observe that the activation of PGC-1a signaling by
SRT1720 seems limited to its action on FAO but, unlike resvera-
trol, does not extend to other PGC-1a-dependent actions. Sev-
eral hypotheses could explain this more restricted activity. The
bioavailability of SRT1720 in metabolic tissues could be distinct
from that of resveratrol and dictate tissue-specific regulations. It
is also possible that the interplay with other metabolically rele-
vant SIRT1 targets such as FOXO1 or p53 (Bensaad and Vous-
den, 2007; Feige and Auwerx, 2008; Frescas et al., 2005; Gross
et al., 2008; Luo et al., 2001; Qiao and Shao, 2006; Vaziri et al.,
2001), which are deacetylated by SRT1720, also modulates the
systemic metabolic response. Alternately, the observation that
specific SIRT1 agonists modulate only a subset of PGC-1a tar-
get promoters in cellular models (Figure S6) suggests that
SRT1720 can drive a selective activation of PGC-1a signaling.
It is well established that SIRT1 is activated by low energetic
levels such as those occurring during fasting or calorie restriction
(Michan and Sinclair, 2007; Rodgers et al., 2005), and it has
been suggested that SIRT1 activators act, at least in part, by stim-
ulating physiological pathways activated by low energetic levels
(Barger et al., 2008; Pearson et al., 2008). Consistently, SRT1720
activates a global network enhancing fat oxidation, a process
also stimulated upon fasting in mammals when fatty acids com-
ing from adipose tissue lipolysis become the prominent energetic
substrate. In this context, it is highly interesting to observe that
prolonged SIRT1 activation by SRT1720 can activate AMPK,
a sensor of low energetic levels, through indirect mechanisms.
It is possible that the recently described SIRT1-dependent regu-
lation of LKB1 plays a role in this regulation (Hou et al., 2008).
However, since SRT1720 does not directly activate AMPK in cel-
lular models or in vivo and energetic levels are reduced in certain
tissues of SRT1720-treated mice, we believe that SRT1720 could
act as a calorie restriction mimetic, which would induce a global
metabolic adaptation similar to what occurs under low energetic
levels. Given the important role of AMPK in inducing oxidative
metabolism in response to low energetic levels, the indirect acti-
vation of this kinase and of its downstream effectors by SRT1720nc.
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Since it has been recently suggested that the response to calorie
restriction varies greatly between tissues (Chen et al., 2008), it
will, therefore, be of importance to precisely characterize how
the tissue-specific response to SIRT1 activators relates to ener-
getic levels of individual organs.
Altogether, our results further validate SIRT1 as a bona fide
target to combat metabolic disorders and establish SRT1720




5-aminoimidazole-4-carboxamide riboside (AICAR; Toronto Research Chem-
icals) was dissolved in 0.9% NaCl, and metformin (Sigma), resveratrol (Orchid
Chemicals), SRT1720, and SRT2183 (Sirtris) were dissolved in DMSO. Viral
constructs for control and SIRT1 shRNAs, as well as PGC-1a WT and R13,
were previously described (Rodgers et al., 2005). CytC and PDK4 reporter
constructs were kind gifts of P. Puigserver and D. Kelly, respectively.
Animal Experiments
Male 7-week-old C57BL/6J mice (Charles River) were housed with a 12 hr
light-dark cycle and fed a standard or HF diet containing 60% energy as fat
(D12492; Research diet), supplemented or not with SRT1720, as described
in Feige et al. (2008). Phenotyping tests and histology were performed accord-
ing to EMPRESS standardized protocols as described in Argmann et al. (2006),
Heikkinen et al. (2007), and Lagouge et al. (2006). For acute experiments,
SRT1720 and AICAR were injected intraperitoneally at 500 mg/kg 4 hr before
the sacrifice. Radiolabeled hyperinsulinemic-euglycemic clamps were per-
formed as described in the Supplemental Experimental Procedures, using
3H-glucose and 14C-2-deoxy-glucose to evaluate glucose turnover and or-
gan-specific glucose uptake, respectively.
Biochemistry and Immunoblotting
Plasmatic parameters and hepatic and fecal lipid content were measured as
previously described (Mataki et al., 2007). Cytochrome C oxidase activity
was evaluated by following the oxidation of fully reduced cytochrome
C (Sigma) at 550 nm, and citrate synthase activity was measured as previously
described (Lagouge et al., 2006). ATP and ADP concentrations were measured
using a luciferase-based assay (Biovision) after acid extraction in 5%
perchloric acid followed by neutralization with potassium carbonate. Western
blots were performed on 0.5–2 mg of total proteins using antibodies directed
against the total or phosphorylated subunit a of AMPK, phosphorylated ACC,
p53, and acetylated p53 and diluted at 1/1000. PGC-1a and FOXO1 acetyla-
tion was evaluated by immunoprecipitating 1000 mg of total proteins from skel-
etal muscle with PGC-1a or FOXO1 antibodies, followed by immunoblotting
against acetylated lysine or against PGC-1a or FOXO1. All antibodies were
from Cell Signaling, and detection was performed using ultrasensitive horse-
radish peroxidase chemiluminescence (Pierce).
Gene Expression Profiling
SYBR-green qPCR and Affymetrix expression arrays were performed as de-
scribed in the Supplemental Experimental Procedures on cDNAs from trizol-
extracted (Invitrogen) RNA samples. Microarrays were analyzed using gene
set enrichment analysis as previously described (Lagouge et al., 2006).
Oxygen Consumption Measurements
Cellular oxygen consumption and palmitate oxidation was measured using
a Seahorse bioscience XF24 analyzer with ten biological replicates per condi-
tion, as described in the Supplemental Experimental Procedures.
Statistics
Statistical analyses were performed with a Student’s t test for independent
samples. Data are expressed as mean ± SEM, and p values smaller than
0.05 were considered as statistically significant.Cell MSUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures
and six figures and can be found with this article online at http://www.
cellmetabolism.org/supplemental/S1550-4131(08)00284-2.
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